A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2
Jing Wen, Jaesu Moon, Luca Tucciarone, Te-Hsuan Bu, Amanda Y. Sun, Robyn Miller, Julia Timis, Lujing Wu, Davey M. Smith, Sujan Shresta, Kyle J. Gaulton, Tariq M. Rana
This study develops a modified SARS-CoV-2 mRNA vaccine, G1-C, that enhances antibody and T cell responses and provides better in vivo protection against the virus.
npj Vaccines · Mar 24, 2026Peer-reviewedImmunology